Targeted Therapy Substantially Decreases Progression Rate in Patients with an Aggressive Form of Thyroid Cancer, Mayo Clinic Reports

ROCHESTER, Minn.--(BUSINESS WIRE)--The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.